Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Depreciation & Amortization (CF) (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $396000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 8.55% to $396000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 19.13% year-over-year, with the annual reading at $1.7 million for FY2025, 19.24% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $396000.0 at Pliant Therapeutics, down from $400000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $600000.0 in Q2 2024, with the low at $396000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $442600.0, with a median of $411500.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 50.0% in 2024, then plummeted 33.33% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $400000.0 in 2021, then rose by 5.75% to $423000.0 in 2022, then decreased by 5.44% to $400000.0 in 2023, then rose by 8.25% to $433000.0 in 2024, then fell by 8.55% to $396000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $396000.0, $400000.0, and $400000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.